

Not for release, publication or distribution in Australia, Canada, Japan or the United States. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the securities of NeuroSearch A/S (the "Securities") in Australia, Canada, Japan or the United States or in any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The issuer of the Securities has not registered, and does not intend to register, any portion of the Offering in the United States, and does not intend to conduct a public offering of the Securities in the United States.

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Announcement

NeuroSearch announces revised financial calendar for 2007 and financial calendar for 2008

Revised financial calendar 2007

NeuroSearch plans to release its third quarter 2007 report on 28 November 2007.

Financial calendar 2008

NeuroSearch's financial calendar for 2008 is as follows:

5 March 2008:	2007 annual report
30 April 2008:	Annual general meeting and first quarter 2008 report
27 August 2008:	2008 half year report
19 November 2008:	Third quarter 2008 report

Asger Aamund
Chairman of the Board

Contacts:

Telephone:

Flemming Pedersen, CEO

+45 4460 8214 or +45 2148 0118

Hanne Leth Hillman, Vice President,
Director of Investor Relations & Corporate
Communications

+45 4460 8212 or +45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the Company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder and Parkinson's disease (Phase I) and ABT-107 as well as ABT-560 for the treatment of various CNS diseases – both (Phase I) in collaboration with Abbott. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.